ArticleFuture virology
Hepatitis C Virus. Strategies to Evade Antiviral Responses.
Article in Future virology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.Microorganisms · 2024Review
- Article
- Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.BMJ case reports · 2023Article
- Article
- A comparative genomics-based study of positive strand RNA viruses emphasizing on SARS-CoV-2 utilizing dinucleotide signature, codon usage and codon context analyses.Gene reports · 2021Article
- Autophagy in HCV Replication and Protein Trafficking.International journal of molecular sciences · 2021Review
- Altered mMolecular cell · 2020Article
- A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection.Frontiers in microbiology · 2020Article
- Review
- Article
- Genetic variants in RIG-I-like receptor influences HCV clearance in Chinese Han population.Epidemiology and infection · 2019Article
- Subversion of cellular autophagy during virus infection: Insights from hepatitis B and hepatitis C viruses.Liver research (Beijing, China) · 2018Article
- The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia.Frontiers in immunology · 2018Review
- Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells.Antiviral research · 2017Article
- Long Non-coding RNAs in Hepatitis C Virus-Infected Cells.Frontiers in microbiology · 2017Review
- The human immune system's response to carcinogenic and other infectious agents transmitted by mosquito vectors.Parasitology research · 2017Review
- Functional evolution of the OAS1 viral sensor: Insights from old world primates.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2016Article
- Mechanisms of Cellular Membrane Reorganization to Support Hepatitis C Virus Replication.Viruses · 2016Review
- Hepatitis C virus NS3-4A inhibits the peroxisomal MAVS-dependent antiviral signalling response.Journal of cellular and molecular medicine · 2016Article
- Status of hepatitis C virus vaccination: Recent update.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatitis C virus (HCV) causes chronic liver disease and poses a major clinical and economic burden worldwide. HCV is an RNA virus that is sensed as non-self in the infected liver by host pattern recognition receptors, triggering downstream signaling to interferons (IFNs). The type III IFNs play an important role in immunity to HCV, and human genetic variation in their gene loci is associated with differential HCV infection outcomes. HCV evades host antiviral innate immune responses to mediate a persistent infection in the liver. This review focuses on anti-HCV innate immune sensing, innate signaling and effectors, and the processes and proteins used by HCV to evade and regulate host innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.